The U.S. Supreme Court has scheduled oral arguments for April 29, 2026, in the case of Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., a pivotal dispute concerning the “skinny label” practice in the pharmaceutical industry. This case addresses whether a generic drug manufacturer can be held liable for induced patent infringement when it markets a product using a label that omits patented uses, yet promotes the product as a generic equivalent of a branded drug.
Hikma Pharmaceuticals sought approval from the Food and Drug Administration (FDA) for a generic version of Amarin’s Vascepa, a medication approved for treating severe hypertriglyceridemia and, later, for reducing cardiovascular risk. To avoid infringing on Amarin’s patents covering the cardiovascular indication, Hikma employed a “skinny label,” excluding this specific use from its product labeling. Despite this omission, Amarin filed a lawsuit alleging that Hikma induced infringement through public statements describing its product as a “generic version” of Vascepa and by referencing Vascepa’s overall sales without distinguishing between the approved indications. ([crowell.com](https://www.crowell.com/en/insights/client-alerts/hikma-and-amici-curiae-ask-supreme-court-to-revisit-induced-infringement-by-generic-skinny-labels?utm_source=openai))
The District Court for the District of Delaware dismissed Amarin’s complaint, concluding that Hikma’s labeling and public statements did not constitute inducement. However, the Federal Circuit reversed this decision, finding that Amarin’s allegations plausibly suggested that Hikma’s conduct could encourage infringing use of the patented cardiovascular indication. ([thepatentplaybook.com](https://www.thepatentplaybook.com/2026/01/supreme-court-takes-up-hikma-v-amarin-induced-infringement-and-skinny-labels-in-the-crosshairs/?utm_source=openai))
Hikma petitioned the Supreme Court for review, arguing that the Federal Circuit’s decision undermines the statutory mechanism allowing generic manufacturers to carve out patented uses, potentially exposing them to litigation despite compliance with FDA labeling requirements. The Supreme Court’s decision to hear the case underscores the significance of clarifying the boundaries of induced infringement liability in the context of generic drug marketing. ([duanemorris.com](https://www.duanemorris.com/alerts/us_supreme_court_grants_certiorari_hikma_amarin_placing_skinny_label_inducement_focus_0126.html?utm_source=openai))
The outcome of this case could have far-reaching implications for the pharmaceutical industry, particularly concerning the balance between protecting patent rights and facilitating the timely entry of generic drugs into the market. Legal professionals and industry stakeholders are closely monitoring the proceedings, as the Court’s ruling may necessitate adjustments in both litigation strategies and marketing practices for generic manufacturers. ([bipc.com](https://www.bipc.com/client-update-supreme-court-takes-up-skinny-labels-granting-certiorari-in-hikma-v.-amarin?utm_source=openai))